- GlaxoSmithKline said a clinical study of its blood cancer treatment had met its primary goal. 'The two-arm study met its primary objective and demonstrated a clinically meaningful overall response rate with belantamab mafodotin in the patient population, the company said. 'The safety and tolerability profile was consistent with that observed in DREAMM-1, the first time in human study of belantamab mafodotin.' The data from the study would be the basis for regulatory filings starting later this year, it added. 'I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment,' said Dr Hal Barron, Chief Scientific Officer and President R&D, GSK .

Story provided by